Asia-Pacific Pharmaceutical Contract Manufacturing Market - By Type , Country, Trends, Forecasts - 2017 - 2022

  • ID: 4389678
  • Report
  • Region: Asia Pacific
  • 82 pages
  • Mordor Intelligence
1 of 4
The APAC Pharmaceutical Contract Manufacturing market is estimated to grow at a compound annual growth rate of 10.52% during the period 2017 - 2022. Active Pharmaceutical Ingredient (API) holds the highest market share, while final dosage form is estimated to be the top growing segment during the forecasted period. The companies in the upstream industry are undergoing restructuring so as to focus more on R&D. Added to this, stringent regulations on the pharmaceutical industry are compelling the companies to outsource the manufacturing of drugs.

Contract manufacturing involves the outsourcing of manufacturing of the products to third party vendors. Pharmaceutical contract manufacturers are then given the chemical formulation of the drug from the pharmaceutical company and then prepare/manufacture in their location. The contract manufacturing market is growing significantly since the pharmaceutical companies are focusing more on R&D of the drugs instead of manufacturing the formulated drug to stay competitive in the market.

Pharmaceutical companies are going for fewer vendors to take volume advantage and at the same time reduce logistics costs. The growing number of innovative drugs is driving the market, while in-house manufacturing is a chief constraint. The final dosage form manufacturing is a major opportunity in this sector.

The market is segmented on the basis of dosage formulation and country. Based on dosage formulation, the contract manufacturing market can be segmented into solid dosage formulation, liquid dosage formulation, and injectable dosage formulation.

This Report Offers:

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Study Deliverables
1.2 Key Findings of the Study
1.3 Market Definition
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Current Market Trends
4.2 Drivers
4.2.1 Growing Innovative drugs
4.2.2 Increasing Investments in R&D
4.3 Restraints
4.3.1 In-house packaging
4.3.2 Capacity Utilization Issues Affecting the Profitability of CMOs
4.3.3 Increasing Lead Time & Logistics Costs
4.4 Market Opportunities
4.4.1 Huge Demand for Next Generation Biological Surgeries
4.5 Porters Five Force Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products and Services
4.5.5 Intensity of Competitive Rivalry
4.6 Industry Value Chain Analysis
4.7 Industry Policies
5. Technology Snapshot
5.1 Dosage Formulation Technologies
5.1.1 Abuse Deterrent Formulation Technology
5.1.2 Lipid Marti-particulate Technology
5.1.3 Dry powder Inhalation Technology
5.1.4 Force Control Agent Technology
5.1.5 High Potency Drug Formulation Technology
5.1.6 Fluidized Bed Coating Technology
5.1.7 Form EZE Technology
5.2 Dosage Forms by Route of Administration
5.2.1 Oral
5.2.2 Topical
5.2.3 Parenteral
5.2.4 Rectal
5.2.5 Vaginal
5.2.6 Inhaled
5.2.7 Ophthalmic
5.2.8 OTIC
6. Asia=Pacific Pharmaceutical Contract Manufacturing Market Segmentation - By Type
6.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.2 Finished Dosage Formulation (FDF) Development and Manufacturing
6.2.1 Solid Dosage Formulation
6.2.2 Liquid Dose/Semi-Solid Formulation
6.2.3 Injectable Dose Formulation
6.3 Secondary Market
7. Pharma CMO Market -Segmented by geography
7.1 Asia-Pacific
7.1.1 Japan
7.1.2 China
7.1.3 India
7.1.4 Others
8. Asia-Pacific Pharmaceutical Contract Manufacturing Vendor Market Share
9. Competitive Intelligence - Company Profiles
9.1 Catalent Inc
9.2 Recipharm AB
9.3 Aptiut LLC
9.4 Patheon Inc
9.5 Daito Pharmaceutical
9.6 AbbVie Inc
9.7 Pfizer Centre Source
9.8 Aenova (Haupt) Group
9.9 Famar Inc
9.10 Baxter Bio Pharma Solutions
9.11 Lonza Group
9.12 Contract Pharmaceuticals Limited
9.13 Confab Inc
10. Investment Analysis
10.1 Recent Mergers & Acquisitions
10.2 Investment Scenario and Opportunities
11. Future of Pharmaceutical Contract Manufacturing Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Note: Product cover images may vary from those shown
Order Online - visit: